Japanese Generic Drug Makers Report Profits
This article was originally published in PharmAsia News
Executive Summary
Major Japanese generic drugs makers Sawai, Towa Yakuhin and Taiyo Yakuhin reported strong third-quarter fiscal results. Sawai achieved double digit increase in both sales and profit (PharmAsia News Feb.12 2009); Towa's sales grew by 13.7 percent to ¥26.6 billion and net profit increased by 6.7 percent to ¥2.5 billion. The company also revised upward for full year estimated sales. Taiyo's sales increased by 13.4 percent to ¥31.9 billion and ordinary profit increased by 14.2 percent to ¥6.1 billion. The growth is a result of the government's generic drug promotion measures. (Click here for more - Japanese language
You may also be interested in...
Sawai Pharmaceutical Achieves Double Digit Growth In Sales And Profits
Japan's largest generic drug maker Sawai increased sales by 16.4 percent and net profit by 32.8 percent in the third quarter, the company reported Feb. 9. Group sales grew to ¥33.41 billion and net profit increased to ¥2.09 billion. Saiwai cited a prescription form change in April 2008 and expanding generics use among dispensing pharmacies. The company also noted that sales to hospitals using diagnostic procedure combined payment systems have increased by 19.6 percent and net profit increased by 32.3 percent, both are record setting numbers for the company. Looking forward, the company looks to have a full year results that overtake last year's. (Click here for more - Japanese language
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.